Peginterferon Alfa-2a (rbe)
Peginterferon Alfa-2a (rbe) Information

About Peginterferon Alfa-2a (rbe)

Peginterferon alfa-2a (rbe) is a polyethylene glycol-conjugated derivative of interferon alpha. Peginterferon alfa-2a (rbe) is licensed for the treatment of chronic hepatitis C, ideally in combination with ribavirin.

Indications

Peginterferon Alfa-2a (rbe) is primarily indicated in conditions like Chronic hepatitis C.

Contraindication

Peginterferon Alfa-2a (rbe) is contraindicated in conditions like Psychiatric disease,Cardiac disease,Hepatic dysfunction,Autoimmune hepatitis.

Side Effects

The symptomatic adverse reactions produced by Peginterferon Alfa-2a (rbe) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Fatigue, Anorexia, Myalgia, Skin reactions, Insomnia, GI upset, Depression, Pyrexia, Anemia, Rigors, Flu like syndrome.

Warnings

Peginterferon alfa-2a (rbe) should only be used by physicians experienced in treatment of hepatitis C. Perform full blood, biochemical and thyroid tests before and during therapy. Suicidal tendencies may occur; ask patients to report any signs of depression. Perform ECG if pre-existing cardiac disease. Modearate hepatic or renal impairment may occur, reduce dose or withdraw if deteriorate. Examine eyes if loss of vision.

High Risk Groups

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.